Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 878-884

  Vesikari, Timo ^a   Karvonen, Aino ^a   Borrow, Ray ^b,c   Kitchin, Nick ^d   Baudin, Martine ^e   Thomas, Stéphane ^e   Fiquet, Anne ^e  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Sanofi Pasteur MSD Ltd   (United Kingdom)

^e SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; MENINGOCOCCUS VACCINE; ROTAVIRUS VACCINE;

ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FINLAND; FLATULENCE; GASTROENTERITIS; HEMATOCHEZIA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BLOOD BACTERICIDAL ACTIVITY; FINLAND; HUMANS; INFANT; MENINGOCOCCAL VACCINES; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED; VACCINES, CONJUGATE; VOMITING;

EID: 79955762423     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00437-10     Document Type: Article

References (25)

1. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
2. Block, S. L., et al. 2007. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 119:11-18. (Pubitemid 46397837)
3. Borrow, R., et al. 2003. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect. Immun. 71:5549-5555.
4. Ciarlet, M., et al. 2009. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheriatetanus- acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr. Infect. Dis. J. 28:177-181.
5. Ciarlet, M., et al. 2008. Concomitant use of the oral pentavalent humanbovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr. Infect. Dis. J. 27:874-880.
6. Collett, D. 2003. Modelling binary data, 2nd ed. Chapman & Hall/CRC, London, United Kingdom.
7. Dennehy, P. H., M. G. Goveia, M. J. Dallas, and P. M. Heaton. 2007. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int. J. Infect. Dis. 11(Suppl. 2):S36-S42.
8. Dormitzer, P. R. 2005. Rotavirus, p. 1902-1913. In G. L. Mandel, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 6th ed. Elsevier Churchill Livingstone, Philadelphia, PA.
9. Farrington, C., and G. Manning. 1990. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat. Med. 9:1447-1454.
10. Giaquinto, C., and P. Van Damme for the REVEAL Study Group. 2010. Age distribution of paediatric rotavirus gastroenteritis cases in Europe: the REVEAL study. Scand. J. Infect. Dis. 42:142-147.
11. Knowlton, D. R., D. M. Spector, and R. L. Ward. 1991. Development of an improved method for measuring neutralizing antibody to rotavirus. J. Virol. Methods 33:127-134.
12. Maslanka, S. E., et al. 1997. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4:156-167.
13. Merck & Co. Inc.,/Sanofi Pasteur MSD. 2006. Summary of product characteristics of RotaTeq. Merck & Co. Inc., Whitehouse Station, NJ/Sanofi Pasteur MSD, Lyon, France. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Product-Information/human/000669/WC500054185.pdf. Accessed 11 November 2009.
14. Miettinen, O., and M. Nurminen. 1985. Comparative analysis of two rates. Stat. Med. 4:213-226.
15. Offit, P., F. Clark, and D. Ward. 2008. Rotavirus vaccine, p. 715-734. In S. A. Plotkin, W. A. Orenstein, and P. A. Offit (ed.). Vaccines, 5th ed. Saunders- Elsevier, Philadelphia, PA.
16. Parashar, U. D., E. G. Hummelman, J. S. Bresee, M. A. Miller, and R. I. Glass. 2003. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9:565-572.
17. Rodriguez, Z. M., et al. 2007. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr. Infect. Dis. J. 26:221-227.
18. Soriano-Gabarró, M., J. Mrukowicz, T. Vesikari, and T. Verstraeten. 2006. Burden of rotavirus disease in European Union countries. Pediatr. Infect. Dis. J. 25(1 Suppl.):S7-S11.
19. Southern, J., A. Crowley-Luke, R. Borrow, N. Andrews, and E. Miller. 2006. Immunogenicity of one, two or three doses of meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24:215-219. (Pubitemid 41753009)
20. Van Damme, P., et al. 2007. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J. Infect. Dis. 195(Suppl. 1):S4-S16.
21. Vesikari, T., et al. 2006. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety, and immunogenicity in healthy infants. Vaccine 24:4821-4829. (Pubitemid 43776799)
22. Vesikari, T., et al. 2009. RotaTeq®, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 28:345-351.
23. Vesikari, T., et al. 2006. Safety and efficacy of pentavalent human-bovine (W3C) reassortant rotavirus vaccine. N. Engl. J. Med. 354:23-33.
24. Vesikari, T., et al. 2008. European Society for Paediatric Infectious Diseases/ European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J. Pediatr. Gastroenterol. Nutr. 46:S38-S48.
25. World Medical Association. Declaration of Helsinki. http://www.the-aps. org/publications/journals/guide.htm. Accessed 11 November 2009.